PD Dr. Peter Dietrich



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Variation of different histone deacetylases and the functional effects of HDAC inhibitors in hepatocellular carcinoma (2019) Freese K, Dietrich P, Boßerhoff AK, Hellerbrand C Conference contribution Profiling of gallbladder carcinoma reveals distinct miRNA profiles and activation of STAT1 by the tumor suppressive miRNA-145-5p (2019) Goeppert B, Truckenmueller F, Ori A, Fritz V, Albrecht T, Fraas A, Scherer D, et al. Journal article The delta subunit of rod-specific photoreceptor cgmp phosphodiesterase (Pde6d) contributes to hepatocellular carcinoma progression (2019) Dietrich P, Hellerbrand C, Boßerhoff AK Journal article Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma (2019) Dietrich P, Gaza A, Wormser L, Fritz V, Hellerbrand C, Boßerhoff AK Journal article BMP6-induced modulation of the tumor micro-milieu (2019) Stieglitz D, Lamm S, Braig S, Feuerer L, Kuphal S, Dietrich P, Arndt S, et al. Journal article ROBOT-ASSISTED PARTIAL NEPHRECTOMY FOR CT2 RENAL TUMORS: PERIOPERATIVE, FUNCTIONAL AND ONCOLOGICAL OUTCOMES FROM A MULTICENTER ANALYSIS (THE ROSULA PROJECT) (2018) Dietrich P Conference contribution Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis (2018) Schmidt KM, Dietrich P, Hackl C, Guenzle J, Bronsert P, Wagner C, Fichtner-Feigl S, et al. Journal article MicroRNA-622 is a novel mediator of tumorigenicity in melanoma by targeting Kirsten rat sarcoma (2018) Dietrich P, Kuphal S, Spruss T, Hellerbrand C, Boßerhoff AK Journal article Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option (2018) Dietrich P, Freese K, Mahli A, Thasler WE, Hellerbrand C, Boßerhoff AK Journal article Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition (2017) Dietrich P, Kuphal S, Spruss T, Hellerbrand C, Boßerhoff AK Journal article
1 2 3 4 5